Meagan Whisenant1, Bob Wong, Sandra A Mitchell, Susan L Beck, Kathi Mooney. 1. Author Affiliations: Division of Internal Medicine, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston (Dr Whisenant); College of Nursing (Drs Wong, Beck, and Mooney) and Huntsman Cancer Institute (Drs Beck and Mooney), University of Utah, Salt Lake City; and Outcomes Research Brant, National Cancer Institute, Rockville, Maryland (Dr Mitchell).
Abstract
BACKGROUND: Women are at risk of mood disturbance during treatment for breast cancer. OBJECTIVE: The aims of this study were to identify classes of women experiencing similar trajectories of depressed mood and anxiety while receiving chemotherapy for breast cancer and to determine associated antecedents and outcomes. The specific aims were to (1) determine the distinct trajectory classes associated with severity of depressed mood and anxiety reported by women undergoing cycles 2 and 3 of chemotherapy for breast cancer, (2) determine if class membership is associated with various antecedent variables, and (3) determine if class membership is associated with days of missed work and hours spent lying down. METHODS: In a secondary analysis, classes were identified using Latent Growth Mixture Modeling. Antecedents and outcomes related to class membership were explored. RESULTS: Participants (n = 166; mean age, 53 [SD, 10.8] years) were mostly white (91.46%); half had early-stage disease. Two trajectories of depressed mood and anxiety were identified. Receipt of doxorubicin was associated with the higher severity class for depressed mood (P < .01) and anxiety (P = .04). No college education (P = .03) or spending more hours lying down (P = .03) was associated with the higher severity class for anxiety. CONCLUSIONS: Distinct trajectories of mood disturbance are distinguished by baseline severity. Further study is needed to determine if biologic or genomic factors are associated with class membership. IMPLICATIONS FOR PRACTICE: Identification of women at risk of mood disturbance may allow clinicians to intensify symptom management. Mood disturbance early in the treatment trajectory warrants management to improve outcomes.
BACKGROUND: Women are at risk of mood disturbance during treatment for breast cancer. OBJECTIVE: The aims of this study were to identify classes of women experiencing similar trajectories of depressed mood and anxiety while receiving chemotherapy for breast cancer and to determine associated antecedents and outcomes. The specific aims were to (1) determine the distinct trajectory classes associated with severity of depressed mood and anxiety reported by women undergoing cycles 2 and 3 of chemotherapy for breast cancer, (2) determine if class membership is associated with various antecedent variables, and (3) determine if class membership is associated with days of missed work and hours spent lying down. METHODS: In a secondary analysis, classes were identified using Latent Growth Mixture Modeling. Antecedents and outcomes related to class membership were explored. RESULTS: Participants (n = 166; mean age, 53 [SD, 10.8] years) were mostly white (91.46%); half had early-stage disease. Two trajectories of depressed mood and anxiety were identified. Receipt of doxorubicin was associated with the higher severity class for depressed mood (P < .01) and anxiety (P = .04). No college education (P = .03) or spending more hours lying down (P = .03) was associated with the higher severity class for anxiety. CONCLUSIONS: Distinct trajectories of mood disturbance are distinguished by baseline severity. Further study is needed to determine if biologic or genomic factors are associated with class membership. IMPLICATIONS FOR PRACTICE: Identification of women at risk of mood disturbance may allow clinicians to intensify symptom management. Mood disturbance early in the treatment trajectory warrants management to improve outcomes.
Authors: Inge Henselmans; Vicki S Helgeson; Howard Seltman; Jakob de Vries; Robbert Sanderman; Adelita V Ranchor Journal: Health Psychol Date: 2010-03 Impact factor: 4.267
Authors: Christine Miaskowski; Bruce A Cooper; Michelle Melisko; Lee-May Chen; Judy Mastick; Claudia West; Steven M Paul; Laura B Dunn; Brian L Schmidt; Marilyn Hammer; Frances Cartwright; Fay Wright; Dale J Langford; Kathryn Lee; Bradley E Aouizerat Journal: Cancer Date: 2014-05-02 Impact factor: 6.860
Authors: Marshall Gold; Laura B Dunn; Bethany Phoenix; Steven M Paul; Deborah Hamolsky; Jon D Levine; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2015-07-15 Impact factor: 2.398
Authors: J A Sloan; C L Loprinzi; S A Kuross; A W Miser; J R O'Fallon; M R Mahoney; I M Heid; M E Bretscher; N L Vaught Journal: J Clin Oncol Date: 1998-11 Impact factor: 44.544
Authors: Kate Oppegaard; Carolyn S Harris; Joosun Shin; Steven M Paul; Bruce A Cooper; Jon D Levine; Yvette P Conley; Marilyn Hammer; Frances Cartwright; Fay Wright; Laura Dunn; Kord M Kober; Christine Miaskowski Journal: Support Care Cancer Date: 2021-06-26 Impact factor: 3.603
Authors: Macarena C Cáceres; Marta Nadal-Delgado; Casimiro López-Jurado; Demetrio Pérez-Civantos; Jorge Guerrero-Martín; Noelia Durán-Gómez Journal: Int J Environ Res Public Health Date: 2022-03-16 Impact factor: 4.614